Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection

BACKGROUND: Internal tandem duplications (FLT3-ITDs) in the FLT3 gene constitute a key driver mutation in acute myeloid leukemia (AML), strongly associated with poor prognosis and therapeutic resistance. Although general-purpose structural variant callers such as Sniffles have been used to detect FL...

Full description

Bibliographic Details
Authors: Martínez-Serra, Jordi; Alonso-Carballo, Aser; Horrillo, Ángel; Gomez Fernandez, Paula; Vögler, Oliver; Gutiérrez, Antonio; Sampol Mayol, Antonia
Format: Article
Publication date:2025
Country:España
Institution:Conselleria de Salut i Consum del Govern de les Illes Balears
Repository:Docusalut
Language:English
OAI Identifier:oai:docusalut.com:20.500.13003/25537
Online Access:https://hdl.handle.net/20.500.13003/25537
Access Level:Open access
Keyword:Leukemia, Myeloid, Acute
Leucemia Mieloide Aguda
AML
FLT3-ITD
TGS
acute myeloid leukemia
minION
third-generation sequencing
_version_ 1878731383706222592
author Martínez-Serra, Jordi
author2 Alonso-Carballo, Aser
Horrillo, Ángel
Gomez Fernandez, Paula
Vögler, Oliver
Gutiérrez, Antonio
Sampol Mayol, Antonia
author2_role author
author
author
author
author
author
author_browse Alonso-Carballo, Aser
Gomez Fernandez, Paula
Gutiérrez, Antonio
Horrillo, Ángel
Martínez-Serra, Jordi
Sampol Mayol, Antonia
Vögler, Oliver
author_facet Martínez-Serra, Jordi
Alonso-Carballo, Aser
Horrillo, Ángel
Gomez Fernandez, Paula
Vögler, Oliver
Gutiérrez, Antonio
Sampol Mayol, Antonia
author_role author
collection Docusalut
description BACKGROUND: Internal tandem duplications (FLT3-ITDs) in the FLT3 gene constitute a key driver mutation in acute myeloid leukemia (AML), strongly associated with poor prognosis and therapeutic resistance. Although general-purpose structural variant callers such as Sniffles have been used to detect FLT3-ITDs, their limitations in resolving clonal diversity and low-frequency variants can lead to underrepresentation of minor clones. These shortcomings highlight the need for a dedicated bioinformatics pipeline. MATERIALS AND METHODS: We developed a custom clustering-based pipeline to overcome the constraints of generic SV callers, leveraging Oxford Nanopore's MinION for sequencing. Our method focuses on FLT3-ITDs by grouping near-identical insertions into biologically meaningful subclones, thereby allowing accurate variant detection of even low-frequency events. The pipeline was benchmarked against capillary electrophoresis (CE) and Sniffles at various thresholds (including 10%, 20%, and 50% allele-frequency cutoffs), with results validated via IGV inspection and cross-mapping. RESULTS: The pipeline successfully detected FLT3-ITDs across all tested samples, including low-frequency variants and diverse subclones that Sniffles overlooked. Analyses uncovered complex multiclonal architectures composed of dominant clones (~20-25% of reads) plus multiple minor subclones differing in length, sequence, and breakpoint. Crucially, our approach identified duplications as short as 15 bp-events often dismissed by conventional SV callers. Comparative analyses showed that Sniffles failed to call several biologically validated ITDs detected by our custom pipeline. CONCLUSION: Third-generation sequencing combined with a tailored clustering strategy enhances the detection of FLT3-ITDs and clonal diversity in AML compared to generic variant callers. This method provides critical insights into subclonal populations driving relapse and therapeutic resistance-particularly in relapsed/refractory AML-underscoring the importance of specialized pipelines for precision medicine in leukemia.
eu_rights_str_mv openAccess
format article
id ES_2e76ca72ccba2ca6249fbbeef10a00f7
institution Conselleria de Salut i Consum del Govern de les Illes Balears
instname_str Conselleria de Salut i Consum del Govern de les Illes Balears
language eng
network_acronym_str ES
network_name_str España
oai_identifier_str oai:docusalut.com:20.500.13003/25537
publishDate 2025
publishDateSort 2025
publisher Taylor & Francis
publisherStr Taylor & Francis
reponame_str Docusalut
spelling Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection Martínez-Serra, Jordi Alonso-Carballo, Aser Horrillo, Ángel Gomez Fernandez, Paula Vögler, Oliver Gutiérrez, Antonio Sampol Mayol, Antonia Leukemia, Myeloid, Acute Leucemia Mieloide Aguda AML FLT3-ITD TGS acute myeloid leukemia minION third-generation sequencing BACKGROUND: Internal tandem duplications (FLT3-ITDs) in the FLT3 gene constitute a key driver mutation in acute myeloid leukemia (AML), strongly associated with poor prognosis and therapeutic resistance. Although general-purpose structural variant callers such as Sniffles have been used to detect FLT3-ITDs, their limitations in resolving clonal diversity and low-frequency variants can lead to underrepresentation of minor clones. These shortcomings highlight the need for a dedicated bioinformatics pipeline. MATERIALS AND METHODS: We developed a custom clustering-based pipeline to overcome the constraints of generic SV callers, leveraging Oxford Nanopore's MinION for sequencing. Our method focuses on FLT3-ITDs by grouping near-identical insertions into biologically meaningful subclones, thereby allowing accurate variant detection of even low-frequency events. The pipeline was benchmarked against capillary electrophoresis (CE) and Sniffles at various thresholds (including 10%, 20%, and 50% allele-frequency cutoffs), with results validated via IGV inspection and cross-mapping. RESULTS: The pipeline successfully detected FLT3-ITDs across all tested samples, including low-frequency variants and diverse subclones that Sniffles overlooked. Analyses uncovered complex multiclonal architectures composed of dominant clones (~20-25% of reads) plus multiple minor subclones differing in length, sequence, and breakpoint. Crucially, our approach identified duplications as short as 15 bp-events often dismissed by conventional SV callers. Comparative analyses showed that Sniffles failed to call several biologically validated ITDs detected by our custom pipeline. CONCLUSION: Third-generation sequencing combined with a tailored clustering strategy enhances the detection of FLT3-ITDs and clonal diversity in AML compared to generic variant callers. This method provides critical insights into subclonal populations driving relapse and therapeutic resistance-particularly in relapsed/refractory AML-underscoring the importance of specialized pipelines for precision medicine in leukemia. Taylor & Francis https://hdl.handle.net/20.500.13003/25537
spellingShingle Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection
Martínez-Serra, Jordi
Leukemia, Myeloid, Acute
Leucemia Mieloide Aguda
AML
FLT3-ITD
TGS
acute myeloid leukemia
minION
third-generation sequencing
title Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection
title_full Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection
title_fullStr Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection
title_full_unstemmed Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection
title_short Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection
title_sort Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection
topic Leukemia, Myeloid, Acute
Leucemia Mieloide Aguda
AML
FLT3-ITD
TGS
acute myeloid leukemia
minION
third-generation sequencing
topic_facet Leukemia, Myeloid, Acute
Leucemia Mieloide Aguda
AML
FLT3-ITD
TGS
acute myeloid leukemia
minION
third-generation sequencing
url https://hdl.handle.net/20.500.13003/25537